GlaxoSmithKline Pharmaceuticals Limited has announced the authorization of four senior executives to determine the materiality of events or transactions for regulatory disclosures to stock exchanges. The disclosure was made on 21st April 2026 in compliance with Regulation 30(5) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Authorized Personnel for Material Event Assessment

The Board of Directors has jointly authorized four key personnel to assess the materiality of events requiring disclosure to BSE and NSE. This authorization ensures streamlined decision-making for regulatory compliance and timely disclosure of material information to investors.

Regulatory Compliance Framework

This authorization falls under Regulation 30(5) of SEBI's Listing Obligation and Disclosure Requirements Regulations, 2015, which mandates listed companies to establish clear protocols for determining material events. The regulation requires companies to designate authorized personnel who can collectively assess whether specific events or transactions meet the materiality threshold for public disclosure.

Corporate Governance Structure

The authorized team represents key functional areas within the organization, combining operational leadership, financial oversight, legal compliance, and corporate secretarial functions. This cross-functional approach ensures comprehensive evaluation of events from multiple business perspectives before making disclosure decisions.

The disclosure was formally communicated to both BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, and The National Stock Exchange of India Limited at Exchange Plaza, Bandra-Kurla Complex, Mumbai. Company Secretary Ajay Nadkarni, who also serves as Vice President – Administration and Real Estate, signed the communication on behalf of the company.

GlaxoSmithKline Pharmaceuticals Limited has filed its quarterly compliance certificate with the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) for the quarter ended March 31, 2026. The submission fulfills the company's regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The pharmaceutical company submitted the certificate on April 9, 2026, in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, confirming the company's adherence to mandatory reporting requirements.

Certificate Details

The compliance certificate was issued by Kfin Technologies Limited, which serves as the company's Registrar and Share Transfer Agent. The certificate covers the dematerialisation activities for the quarter ended March 31, 2026.

Dematerialisation Compliance

Kfin Technologies Limited confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed. The registrar verified that:

• Securities received for dematerialisation were confirmed to depositories
• All securities were listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were mutilated and cancelled after verification
• Depository names were substituted in the register of members as registered owners within the stipulated 30-day period

Corporate Information

The certificate was signed by Dnyanesh Gharote, Vice President at Kfin Technologies Limited. GlaxoSmithKline Pharmaceuticals Limited operates from its registered office at GSK House, Dr. Annie Besant Road, Worli, Mumbai, with CIN L24239MH1924PLC001151.

This routine compliance filing demonstrates the company's commitment to maintaining transparency and adhering to SEBI regulations governing depositories and share transfer processes.